NYSE: KVUE · Household & Personal Products
Kenvue (KVUE) fair value: undervalued or overvalued?
As of 3 Oct 2026, Faircurve's model values Kenvue (KVUE) at $17.85 a share. The stock last closed at $17.20, which puts the model's fair value 3.8% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Kenvue Inc.
Faircurve Insights · 3 Oct 2026
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health.
Faircurve's model valued Kenvue Inc. on 3 Oct 2026 at a fair value of $17.85 a share, the midpoint of 2,000 simulations. The previous run, on 26 Sep 2026, gave $18.51, meaning the fair value moved -3.6%. The calibrated range over 63 trading days is $15.80 to $19.79. Ranges built this way held the price 60% of the time at this horizon, and the model's evidence grade is Medium.
The company's overall quality score against comparable companies is 46 out of 100. The model compares it with The Estée Lauder Companies Inc., Kimberly-Clark Corporation, Church & Dwight Co., Inc., Colgate-Palmolive Company, The Clorox Company, e.l.f. Beauty, Inc., Reynolds Consumer Products Inc., and Inter Parfums, Inc. The median size of moves around the last 8 earnings reports, ignoring direction, was 2.5%.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give KVUE?
The calibrated range for KVUE over 63 trading days is $15.80 to $19.79. It sits around the last close, and its width comes from the volatility that KVUE's own options imply (32% a year), calibrated weekly against realised prices (n = 3,562 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $14.51 to $21.51. In 56% of the simulations the fair value came out above the price the model ran on.
How does KVUE score on business quality?
Kenvue's overall quality score is 46 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 31 | 12.5%ROIC | 16.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 61 | 1.28xFCF / net income | 0.99x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 45 | -2.1%Revenue growth, trailing | -2.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 64 | 0.2%Net buybacks / market value | 0.5% |
| Balance sheetNet debt to EBITDA and interest coverage. | 38 | 2.33xNet debt / EBITDA | 1.75x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 48 | 2.0 ptsEBITDA margin downside volatility, 5y | 1.9 pts |
How does KVUE compare with similar companies?
The companies in household & personal products closest to Kenvue in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| EL The Estée Lauder Companies Inc. | $91.97 | $92.30 | +0.4% | Fairly valued |
| KMB Kimberly-Clark Corporation | $94.36 | $105.96 | +12.3% | Fairly valued |
| CHD Church & Dwight Co., Inc. | $94.31 | $87.71 | -7.0% | Fairly valued |
| CL Colgate-Palmolive Company | $84.26 | $90.10 | +6.9% | Fairly valued |
| CLX The Clorox Company | $80.41 | $84.29 | +4.8% | Fairly valued |
| ELF e.l.f. Beauty, Inc. | $104.68 | $100.16 | -4.3% | Fairly valued |
| REYN Reynolds Consumer Products Inc. | $22.32 | $23.01 | +3.1% | Fairly valued |
| IPAR Inter Parfums, Inc. | $113.95 | $122.97 | +7.9% | Fairly valued |
All household & personal products stocks ranked by gap to fair value
When does KVUE report earnings, and how has the stock reacted?
Kenvue's next earnings report is scheduled for 2 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 4.6% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction. KVUE's 30 day implied volatility works out to about 9.2% over one month.
How KVUE moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 2.5%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | -2.2% |
| 7 May 2026 | -0.5% |
| 17 Feb 2026 | +1.0% |
| 3 Nov 2025 | +11.1% |
| 7 Aug 2025 | -0.5% |
| 8 May 2025 | +5.8% |
| 6 Feb 2025 | -2.7% |
| 7 Nov 2024 | +5.2% |
Kenvue at a glance
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health.
- Market value
- $33.0B
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Revenue expected, next twelve months
- $15.9B
- Consensus revenue growth, next fiscal year
- +3.2%
- Analysts with estimates
- 8
- Beta to the US market
- 0.13
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices Kenvue on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for KVUE was $18.51. As of 3 Oct 2026 it is $17.85, a change of -3.6%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Kenvue's valuation
Is Kenvue stock undervalued or overvalued?
On Faircurve's model, KVUE reads as Fairly valued as of 3 Oct 2026. The model's fair value is $17.85 a share against a last close of $17.20, a gap of +3.8%.
What is KVUE's fair value?
$17.85 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $14.51 to $21.51.
What price range does the model give KVUE?
$15.80 to $19.79 over 63 trading days. Ranges built this way held the price 60% of the time across 3,562 past valuations, refreshed 3 Oct 2026.
When does Kenvue report earnings next?
The next report is scheduled for 2 Nov 2026. Companies can move their dates.
How much has KVUE moved on past earnings reports?
Across its last 8 reports the median two session move was 2.5%, ignoring direction. The largest was +11.1% around the report of 3 Nov 2025.
How confident is the model in this valuation?
The model's evidence grade for KVUE is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.